Compare ResMed Inc. (RMD) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs NEOS S&P 500 High Income ETF — how do they compare? ResMed Inc. trades at $196 (market cap $28.81B), while NEOS S&P 500 High Income ETF trades at $53.41. The key difference: ResMed Inc. pays a 1.21% dividend while NEOS S&P 500 High Income ETF pays none, and NEOS S&P 500 High Income ETF is trading nearer its 52-week high, ResMed Inc. nearer its low. Which is the better fit depends on your goals.
| RMD | SPYI | |
|---|---|---|
Market Cap | $28.81B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $293.73 | $54.07 |
52-Week Low | $182.82 | $47.98 |
Enterprise Value | $27.99B | — |
Dividend Yield | 1.21% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SPYI, the NEOS S&P 500 High Income ETF, trades at $53.01, down 0.11% on the day. The technical outlook is bearish based on moving averages, with neutral oscillators. The fund has surpassed $10 billion in assets under management and delivers consistent monthly distributions, with a yield around 12%. Recent news highlights its appeal for income-focused investors seeking S&P 500 exposure with lower volatility.
The outlook for SPYI is supported by strong investor demand for high-yield income solutions, though the bearish technical signal and reliance on options strategies present risks. The fund's ability to generate income without significant NAV erosion remains a key advantage in volatile markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →
